Notizie ed eventi
Collaboration with AstraZeneca
Omron Healthcare Agrees on a Comprehensive and Long-term Global Strategic Collaboration for Joint Research and Development with AstraZeneca PLC London UK, 14th November 2019 – Omron Healthcare Co., Ltd. (Head Office: Kyoto, Japan, President and CEO: Isao Ogino; “Omron Healthcare”) announced that it has agreed with AstraZeneca PLC (Head Office: Cambridge, UK; CEO: Pascal Soriot) …
Omron Healthcare Agrees on a Comprehensive and Long-term Global Strategic Collaboration for Joint Research and Development with AstraZeneca PLC
London UK, 14th November 2019 – Omron Healthcare Co., Ltd. (Head Office: Kyoto, Japan, President and CEO: Isao Ogino; “Omron Healthcare”) announced that it has agreed with AstraZeneca PLC (Head Office: Cambridge, UK; CEO: Pascal Soriot) to enter into a comprehensive and long-term global strategic collaboration for joint research and development to develop disease management solutions for patients, and thus concluded the signing of a memorandum of understanding (MoU).
Both companies share the same vision of improving lives and contributing to a better society through translating science and technology to support our efforts to improve the whole patient experience. Under this agreement, the two companies will combine the strength of each such as knowledge in diseases or solution-creation abilities and global specialist networks, to transform the way we improve patient’s outcomes by establishing an ecosystem around holistic patient journey with companies providing drug, device, diagnostics and digital tools focusing on Respiratory, Cardiovascular and Metabolism therapy area.
This MoU between Omron Healthcare and AstraZeneca builds on several existing successful collaborations including on the delivery of metabolic management centres for patients with diabetes in China, establishing more than 15,000 paediatric nebulization rooms for the treatment of acute asthma in China, co-promotion in Indonesia and Korea. The two companies agreed to leverage know-how gained through the previous partnership and expand from commercial to Research and Development, geographically from China to global scale to cover the below specific strategic:
R&D in the fields of respiratory, cardiovascular and metabolic diseases to meet unmet medical needs of patients;
Development of comprehensive disease management solutions, utilizing IoT technologies, from diagnosis to treatment;
Development of a business model to broaden disease management solutions based on technology and innovation by both companies.
Isao Ogino, President and CEO, Omron Healthcare, said “I believe that our joint efforts with AstraZeneca will be a significant step forward towards achieving our ‘Zero Asthma Events’ vision for our respiratory disease business. By leveraging technologies through our collaboration with AstraZeneca, we aim to develop highly value-added solutions for areas from diagnosis and treatment to daily disease management.”
Leon Wang, EVP, AstraZeneca, said “We are very excited that our collaboration with Omron Healthcare has evolved into a comprehensive and long-term collaboration to cover more therapeutic areas and benefit patient in more regions globally. With the support and cooperation from experts within our global network, we plan to join efforts with Omron Healthcare to enable holistic disease management, from diagnosis to post-treatment care along the patient journey and improve patient outcomes.”
Omron Healthcare will keep striving to contribute to the advancement of the medical treatment by not just providing the products, but also strengthening in the development of valuable service in the area of prevention.
About OMRON Healthcare
As a world leader in innovative and clinically proven medical equipment for health monitoring and treatment, OMRON Healthcare is committed to offering everyone a fuller and richer life without any compromises. OMRON Healthcare is the global market leader in electronic blood pressure monitors, with more than 200 million units sold, and nebulizers used for the treatment of respiratory diseases. The company’s other major product categories include pain relievers, electronic thermometers and scales for body analysis. For decades, OMRON products have helped prevent, treat and control medical conditions, both at home and in clinical settings, in more than 110 countries worldwide. The head office of the OMRON Healthcare Group is located in Kyoto (Japan). OMRON Healthcare Europe Ltd. comprises the healthcare branch for Europe, Russia, the Middle East and Africa, which provides services to clients in more than 74 countries.